Thomas Büttner

12PUBLICATIONS
108CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsLiquid biopsiesCancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Sep 09, 2026
Integrating NECTIN4 Amplification With Membranous Nectin-4 Expression to Develop a Scoring System for Predicting Enfortumab Vedotin Response in Urothelial Carcinoma.

|Sep 08, 2026
External validation of the bellmunt risk score for survival prediction in mCRPC patients undergoing [177Lu]Lu-PSMA-617 therapy.

|Jan 07, 2026
Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study.

Thomas Büttner, Mimma Rizzo, Laura Bernal Vaca

|Oct 29, 2025
Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors-Data From the ARON-1 Study.

Francesco Massari, Matteo Rosellini, Bohuslav Melichar

|Jul 22, 2025
Association of fluid management during robotic-assisted radical laparoscopic prostatectomy with early surgical clinical outcomes: a risk factor for lymphoceles.

Thomas Büttner, Marcus O Thudium, Manuel Ritter

|Jul 08, 2025
Geographical Differences in the Management and Outcomes of Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab After Progression on Platinum-Based Chemotherapy: Results From ARON-2 Study.

Mimma Rizzo, Andrey Soares, Shilpa Gupta

Pageof 2

Frequent Collaborators

5 joint publications

Jörg Ellinger

4 joint publications

Niklas Klümper

3 joint publications

Christopher Darr

3 joint publications

Manuel Ritter